Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Diabetic neuropathy (DN) is the most common chronic complication of diabetes, affecting up
to50% of individuals with type 1 diabetes (T1DM).
Multiple pre-clinical and clinical studies demonstrate a pathogenic role for inflammation,
especially cytokine production, in the disease course of DN and CAN. This suggests that
agents with known anti-inflammatory properties, such as salicylates, may prevent the
development of DN and the pain associated with DN. This study builds upon and expands on
prior work done by the investigators with salsalate, a pro-drug form of salicylate, as an
agent to address inflammatory pathways in people with T1DM.